Administration secures 10 million courses of Pfizer COVID-19 oral antiviral

The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration approves or authorizes the drug for emergency use, the administration announced today. Pfizer has requested an emergency use authorization for the drug, which it says reduced the risk of COVID-19-related hospitalization or death by 89% in a phase 2/3 clinical trial. AHA will provide additional information regarding the drug’s distribution and uses once FDA approval is attained and the Administration shares its plans for allocating the available courses of medication.